Status:
UNKNOWN
Post-stroke Epilepsy: Primary Prophylaxis Study
Lead Sponsor:
National Cheng Kung University
Collaborating Sponsors:
Ministry of Science and Technology, Taiwan
National Cheng-Kung University Hospital
Conditions:
Middle Cerebral Artery Stroke
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Advance in stroke treatment have resulted in a dramatic reduction in the stroke mortality, however, the number of stroke survivors living with morbidity has increased significantly. As we know, post-s...
Detailed Description
Advance in stroke treatment have resulted in a dramatic reduction in the stroke mortality, however, the number of stroke survivors living with morbidity has increased significantly. Among the morbidit...
Eligibility Criteria
Inclusion
- Patients with acute MCA infarct (NIHSS \> 8) and confirmed by brain MRI studies (excluding lacunar infarct) during hospital admission
Exclusion
- Patients with prior clinical history of major stroke, significant head injury, brain tumor, major psychiatric illness, progressive neurodegenerative disorder, CNS infection, epilepsy, which might be precipitating to seizures or history of use of AEDs, including LEV or PER, during pregnancy or lactation, history of inadequate medical compliance, or any other significant major systemic disease with safety concern, determined by physician
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2023
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04858841
Start Date
August 1 2020
End Date
July 31 2023
Last Update
April 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cheng Kung University Hospital
Tainan, Taiwan, 701